75 TRENDS IN PREVALENCE AND ANTITHROMBOTIC PRESCRIPTIONS IN AF FUNDING This study did not receive funding. AdB is supported by the Facts and Figures grant from the Dutch Heart foundation. GJG is supported by a VENI and VIDI grant from the Netherlands Organisation for Health Research and Development (ZonMw numbers 016.166.030 and 016.196.304). POTENTIAL CONFLICTS OF INTEREST FR and GJG report unrestricted institutional grants for performing research in the field of atrial fibrillation from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb/Pfizer Alliance and Daiichi Sankyo. The other authors declare that they have no conflicts of interest. CONTRIBUTORS LJ, AdB, EvE, MB and GJG conceived and initiated the study. EvE prepared the dataset. LJ and EvE performed the statistical analyses. LJ, Eve, AdB and GJG interpreted the results. LJ and AdB wrote the first version of the manuscript. All authors critically reviewed and revised the manuscript. 5
RkJQdWJsaXNoZXIy MTk4NDMw